CG Oncology, Inc. Common stock
$54.42
-0.85%CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -26.2).
Valuation inputs: P/E -26.2, earnings yield N/A, momentum -0.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -21.4%, ROIC -25.1%).
Profitability stack: net margin -39.9%, ROE -21.4%, ROIC -25.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +4.9%, momentum -0.9%, net margin -39.9%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
CG Oncology, Inc. Common stock Market vs Earnings Trajectory
Loading price and EPS data...
CG Oncology, Inc. Common stock Fair Value Envelope
CG Oncology, Inc. Common stock Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
CG Oncology, Inc. Common stock Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
CG Oncology, Inc. Common stock Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
CG Oncology, Inc. Common stock Street Expectations Map
Wall Street analysts project that CGON stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 82.57, with estimates ranging from a low of 70.00 to a high of 93.00.
The consensus 1-year price target stands at 82.57, with estimates ranging from a low of 70.00 to a high of 93.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
CG Oncology, Inc. Common stock Insider Positioning
During the last 12 months, insiders have purchased $50.00M and sold $3.41M worth of CGON shares, resulting in $46.59M of net buying activity.
3 Months
0
0.00
16.9K
1.22M
-1.2M
-$1.22M
3-6 Months
0
0.00
654
28.88K
-29K
-$29K
6-9 Months
1.5M
50.00M
49.3K
1.96M
+48.0M
+$48.04M
9-12 Months
0
0.00
6.2K
190.31K
-190K
-$190K
Top Buyers
Liu Brian Guan-Chyun
Director
$50.00M
Top Sellers
Mulay James
Director
$3.00M
Post Leonard E
Director
$404K
Song Hong Fang
Director
$3K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $46.59M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
CGON has not reported any dividend yield values in the available annual periods.
cgon Dividend History
Learning Layer
Related Guides
Build conviction on CGON by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.